{"id":72286,"date":"2026-08-11T13:17:11","date_gmt":"2026-08-11T05:17:11","guid":{"rendered":"https:\/\/flcube.com\/?p=72286"},"modified":"2026-08-11T13:17:12","modified_gmt":"2026-08-11T05:17:12","slug":"gan-lee-pharmaceuticals-signs-out-licensing-deal-with-menarini-on-bonfaglutide-a-twice-monthly-glp-1-ra-worth-up-to-eur-726-million-across-39-european-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72286","title":{"rendered":"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gan &amp; Lee Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/603087:SHA\">SHA: 603087<\/a>)<\/strong> announced an <strong>out\u2011licensing agreement<\/strong> with <strong>Menarini<\/strong> for <strong>Bonfaglutide Injection (development code: GZR18)<\/strong>, a novel once\u2011every\u2011two\u2011weeks <strong>GLP\u20111 receptor agonist (GLP\u20111 RA)<\/strong>. The deal is worth up to <strong>EUR 726 million<\/strong> excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across <strong>39 European countries and regions<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Gan &amp; Lee Pharmaceuticals (SHA: 603087)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Menarini<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Bonfaglutide Injection (development code: GZR18)<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>Out\u2011licensing agreement<\/td><\/tr><tr><td><strong>Licensed Territory<\/strong><\/td><td>39 European countries and regions<\/td><\/tr><tr><td><strong>Licensee Responsibilities<\/strong><\/td><td>Regulatory filing and commercialization<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-terms\" class=\"wp-block-heading\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>EUR 62 million<\/td><\/tr><tr><td><strong>Potential Milestone Payments<\/strong><\/td><td>Up to EUR 664 million<\/td><\/tr><tr><td><strong>Total Potential Deal Value<\/strong><\/td><td>Up to <strong>EUR 726 million<\/strong> (excluding royalties)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td><strong>Tiered double\u2011digit royalties<\/strong> on net product sales in the licensed territory<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-licensed-territory\" class=\"wp-block-heading\">Licensed Territory<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Menarini will be responsible for regulatory filing and commercialization of Bonfaglutide in <strong>39 European countries and regions<\/strong>, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The <strong>27 EU member states<\/strong><\/li>\n\n\n\n<li>The <strong>UK<\/strong><\/li>\n\n\n\n<li><strong>Switzerland, Norway, Iceland, Liechtenstein<\/strong><\/li>\n\n\n\n<li>The <strong>Balkan region<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-bonfaglutide-gzr18\" class=\"wp-block-heading\">Drug Profile \u2013 Bonfaglutide (GZR18)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Molecule<\/strong><\/td><td>Bonfaglutide Injection (GZR18)<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Novel <strong>glucagon\u2011like peptide\u20111 receptor agonist (GLP\u20111 RA)<\/strong><\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td><strong>Once\u2011every\u2011two\u2011weeks<\/strong> administration<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>Independently developed by Gan &amp; Lee<\/td><\/tr><tr><td><strong>Category<\/strong><\/td><td><strong>Category 1 innovative drug<\/strong><\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Obesity\/overweight, type 2 diabetes mellitus (T2DM), and other metabolic diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence\" class=\"wp-block-heading\">Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Indication<\/th><th>Region<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Pivotal Phase 3<\/strong><\/td><td>Weight management in obesity and overweight<\/td><td>China<\/td><td><strong>Primary endpoints met<\/strong><\/td><\/tr><tr><td><strong>Phase 2<\/strong><\/td><td>Weight management in obesity and overweight<\/td><td>United States<\/td><td><strong>Primary endpoints met<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-differentiation\" class=\"wp-block-heading\">Competitive Differentiation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Compared with traditional <strong>weekly GLP\u20111 RA formulations<\/strong>, Bonfaglutide <strong>reduces injection frequency by approximately 50%<\/strong> \u2014 a meaningful convenience advantage that could improve patient adherence in chronic weight management and diabetes treatment.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-impact\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiated Dosing in a Crowded Field:<\/strong> In the intensely competitive <strong>GLP\u20111 RA market<\/strong>, Bonfaglutide&#8217;s <strong>once\u2011every\u2011two\u2011weeks<\/strong> dosing offers a clear differentiator against weekly incumbents, potentially capturing patients who prioritize injection convenience.<\/li>\n\n\n\n<li><strong>Europe\u2011Wide Scale:<\/strong> Licensing across <strong>39 countries and regions<\/strong> \u2014 including all 27 EU member states \u2014 gives Bonfaglutide one of the broadest European footprints for a China\u2011origin GLP\u20111 asset, executed through Menarini&#8217;s established European commercial infrastructure.<\/li>\n\n\n\n<li><strong>De\u2011Risked Asset:<\/strong> With primary endpoints already met in both a <strong>pivotal Phase 3 trial in China<\/strong> and a <strong>Phase 2 trial in the US<\/strong>, the asset enters the partnership with validated clinical efficacy across two major regulatory jurisdictions.<\/li>\n\n\n\n<li><strong>Value Realization for Gan &amp; Lee:<\/strong> The EUR 726 million potential deal value plus tiered double\u2011digit royalties represents significant monetization of Gan &amp; Lee&#8217;s independently developed metabolic franchise while retaining upside in its home market.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Bonfaglutide&#8217;s regulatory filings, milestone achievement, and commercial performance in Europe. Actual results may differ due to risks including regulatory decisions, market adoption, and competitive dynamics in the GLP\u20111 RA class.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gan &amp; Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[421,4361,1047],"class_list":["post-72286","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gan-lee-pharmaceuticals","tag-hot-targets","tag-menarini"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gan &amp; Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist (GLP\u20111 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72286\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets\" \/>\n<meta property=\"og:description\" content=\"Gan &amp; Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist (GLP\u20111 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72286\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T05:17:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-11T05:17:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72286#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72286\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets\",\"datePublished\":\"2026-08-11T05:17:11+00:00\",\"dateModified\":\"2026-08-11T05:17:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72286\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gan &amp; Lee Pharmaceuticals\",\"Hot targets\",\"Menarini\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72286#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72286\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72286\",\"name\":\"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-11T05:17:11+00:00\",\"dateModified\":\"2026-08-11T05:17:12+00:00\",\"description\":\"Gan & Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist (GLP\u20111 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72286#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72286\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72286#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Gan & Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist (GLP\u20111 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72286","og_locale":"en_US","og_type":"article","og_title":"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets","og_description":"Gan & Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist (GLP\u20111 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.","og_url":"https:\/\/flcube.com\/?p=72286","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-11T05:17:11+00:00","article_modified_time":"2026-08-11T05:17:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72286#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72286"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets","datePublished":"2026-08-11T05:17:11+00:00","dateModified":"2026-08-11T05:17:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72286"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gan &amp; Lee Pharmaceuticals","Hot targets","Menarini"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72286#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72286","url":"https:\/\/flcube.com\/?p=72286","name":"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-11T05:17:11+00:00","dateModified":"2026-08-11T05:17:12+00:00","description":"Gan & Lee Pharmaceuticals (SHA: 603087) announced an out\u2011licensing agreement with Menarini for Bonfaglutide Injection (development code: GZR18), a novel once\u2011every\u2011two\u2011weeks GLP\u20111 receptor agonist (GLP\u20111 RA). The deal is worth up to EUR 726 million excluding royalties, with Menarini taking responsibility for regulatory filing and commercialization across 39 European countries and regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72286#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72286"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72286#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gan &amp; Lee Pharmaceuticals Signs Out\u2011Licensing Deal With Menarini on Bonfaglutide, a Twice\u2011Monthly GLP\u20111 RA, Worth Up to EUR 726 Million Across 39 European Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72286"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72286\/revisions"}],"predecessor-version":[{"id":72288,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72286\/revisions\/72288"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}